Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome

NCT05577988 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2468

Enrollment

OTHER

Sponsor class

Conditions

MYOCARDIAL INFARCTION

Interventions

OTHER: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]